Crovalimab

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 54 publications

Improvement in anemia and symptoms after switching from crovalimab to iptacopan in paroxysmal nocturnal hemoglobinuria.

Improvement in anemia and symptoms after switching from crovalimab to iptacopan in paroxysmal nocturnal hemoglobinuria.

Journal: Hematology (Amsterdam, Netherlands)

Published: January 29, 2026

Advancing treatment goals for paroxysmal nocturnal hemoglobinuria to align with quality of life improvements in the era of anti-complement therapy

Advancing treatment goals for paroxysmal nocturnal hemoglobinuria to align with quality of life improvements in the era of anti-complement therapy

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: January 12, 2026

Crovalimab Rescue Therapy in a Case With Genetic Complement Mediated Thrombotic Microangiopathy.

Crovalimab Rescue Therapy in a Case With Genetic Complement Mediated Thrombotic Microangiopathy.

Journal: Kidney medicine

Published: January 08, 2026

Therapeutic Antibodies in Hematology: Advances in Malignant and Non-Malignant Disorders.

Therapeutic Antibodies in Hematology: Advances in Malignant and Non-Malignant Disorders.

Journal: Cells

Published: December 02, 2025

New Anticomplement Drugs in Nephrology - Mechanism and Indication.

New Anticomplement Drugs in Nephrology - Mechanism and Indication.

Journal: Kidney & blood pressure research

Published: November 28, 2025

Donor-Derived Cell-Free DNA (dd-cfDNA) as an Early Noninvasive Biomarker of Graft Injury in Pig-to-Monkey Islet Xenotransplantation.

Donor-Derived Cell-Free DNA (dd-cfDNA) as an Early Noninvasive Biomarker of Graft Injury in Pig-to-Monkey Islet Xenotransplantation.

Journal: Xenotransplantation

Published: November 11, 2025

Paroxysmal Nocturnal Hemoglobinuria in Patients with Systemic Lupus Erythematosus: Diagnostic Challenges and Improvement with C5 Inhibitor Treatment.

Paroxysmal Nocturnal Hemoglobinuria in Patients with Systemic Lupus Erythematosus: Diagnostic Challenges and Improvement with C5 Inhibitor Treatment.

Journal: Internal medicine (Tokyo, Japan)

Published: October 22, 2025

Progress in the use of biological therapies to treat paroxysmal nocturnal hemoglobinuria: focus on patient profiling.

Progress in the use of biological therapies to treat paroxysmal nocturnal hemoglobinuria: focus on patient profiling.

Journal: Expert opinion on biological therapy

Published: October 13, 2025

Challenges in optimizing targeted complement inhibitor therapy for paroxysmal nocturnal hemoglobinuria in an expanding treatment landscape

Challenges in optimizing targeted complement inhibitor therapy for paroxysmal nocturnal hemoglobinuria in an expanding treatment landscape

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: October 01, 2025

New treatment strategies for paroxysmal nocturnal hemoglobinuria: drug selection in the era of novel complement inhibitors

New treatment strategies for paroxysmal nocturnal hemoglobinuria: drug selection in the era of novel complement inhibitors

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: September 03, 2025

Comparative Efficacy of Complement Inhibitors in Complement Inhibitor-Naïve PNH: A Systematic Review With Supportive Exploratory Network Meta-Analysis of Randomized Trials.

Comparative Efficacy of Complement Inhibitors in Complement Inhibitor-Naïve PNH: A Systematic Review With Supportive Exploratory Network Meta-Analysis of Randomized Trials.

Journal: EJHaem

Published: August 29, 2025

Efficacy and Safety of the C5 Inhibitor Crovalimab in Patients With Paroxysmal Nocturnal Hemoglobinuria: A Systematic Review and Meta-Analysis.

Efficacy and Safety of the C5 Inhibitor Crovalimab in Patients With Paroxysmal Nocturnal Hemoglobinuria: A Systematic Review and Meta-Analysis.

Journal: European journal of haematology

Published: August 11, 2025

Showing 1-12 of 54

Last Updated: 04/28/2026